India Pesticides Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mvn0v5kr7fni7ne0mimrel5m.pdf

Key Takeaways


The Inventory Shock

S. P. Gupta: "See we are not hoping for any significant losses since we have provided for inventory, as per NRV. Maybe 1% or 2% may be there, but most of the losses, they have been provided for in this June quarter."

Price & Margin Mechanics

D.K. Jain: "So, we expect to maintain the EBITDA margins of around 20%, and we will try our best to improve this further on by proper selection of the molecules. We are in always search of molecules for this niche areas."

Demand & Destocking

D. K. Jain: "The prices are still slightly falling sir, because when we talk about what is happening, then the customers, whenever they quote a price, they would like to quote a lower price. That is how things are going on and everybody is in wait and watch mode somehow because they don't want to make all their purchases at the same time."

New Products & Pipeline


Capex & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Inventory reductionReduce inventory by ₹20 crores from current levelsBy end of Q2 FY24
No further significant inventory lossesOnly 1-2% possible unless unforeseen price revision in Aug-SepQ2 FY24
New products contribution₹170-175 crores revenue from new productsFY24
Top line growth~10% growth if situation normalizesFY24 (second-half dependent)
EBITDA marginMaintain ~20%, band of 18-20%FY24
Destocking endsDestocking cycle over3-4 months
Hamirpur first product launchFirst product from new plantQ4 FY24
US supply beginsStart supplying to US market, ~₹20 crores orderedFrom next month onwards
Pharma intermediates commercializationCommercial launchFY25 (Q1 or max Q2)
FY25 revenue growthAt least 15% (previously 20-25%, rationalized for lower product prices)FY25
Long-term consolidated growthMore than 20%Long-term basis

Key Metrics

MetricQ1 FY24
Revenue₹204.7 cr, compared to ₹221.7 cr in Q1 FY23
EBITDA₹26 cr
EBITDA margin (adjusted for inventory loss)~21%, compared to historical 27–28%
PAT₹16 cr, compared to ₹41 cr in Q1 FY23
Inventory loss impact (destocking/NRV)₹17 cr, comprising ₹7.3 cr on sales and ₹9.8 cr on inventory revaluation
Revenue from exports₹84 cr, compared to ₹101 cr in Q1 FY23; 42% of overall sales
Domestic revenue₹117 cr, similar to Q1 FY23
Technical revenue₹158 cr
Formulations revenue₹43 cr
Volume de-growth (YoY)8–10%
FY24 revenue growth guidance~10%, if situation normalizes in H2
FY25 revenue growth guidanceat least 15%
Long-term consolidated growth targetmore than 20%
Contribution from new products₹40 cr in Q1; FY24 expectation ₹170–175 cr
Capacity utilizationslightly more than 50%
Capex incurred in Q1 (Sandila expansion)₹16 cr
FY24 capex plan (IPL)₹50 cr
FY24 capex plan (Shalvis Specialities)₹60 cr
Cash and cash equivalents₹136 cr at end of Q1
Inventory₹190 cr at end of June, down from ₹225 cr in March; expected to reduce by ₹20 cr by end of Q2
Working capital daysreduced by 20 days from March 2023 levels
Asset turnover expectation (Sandila and Hamirpur)2.25x to 2.5x
US client order for FY24~₹20 cr
Raw material sourcing from China~17% of total raw materials (per an analyst's math)